A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Basic science
Enrollment
32actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-19 | actual | When the study began enrolling |
| Primary completion | 2026-06-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-11 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: ABBV-277
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFMaximum Plasma Concentration (Cmax) of ABBV-277
measured Up to approximately 9 days
Time to Cmax (Tmax) of ABBV-277
measured Up to approximately 9 days
Terminal Phase Elimination Rate Constant (Beta) of ABBV-277
measured Up to approximately 9 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-277
measured Up to approximately 9 days
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-277
measured Up to approximately 9 days
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-277
measured Up to approximately 9 days
Number of Participants With Adverse Events (AEs)
measured Up to Day 196
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed